Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IDMC recommends continuation of Cel-Sci's pivotal trial of Multikine

Nov. 7, 2013

ImmunoGen discontinues IMGN-901 study in small-cell lung cancer

Nov. 6, 2013

3pRNA RIG-I agonist displays activity against melanoma

Nov. 6, 2013

CureVac collaborates with the Cancer Research Institute and Ludwig Cancer Research

Nov. 6, 2013

arGEN-X and de Duve Institute/UCL sign collaboration to develop immunomodulation therapy for cancer

Nov. 5, 2013

Farletuzumab misses phase II endpoint for NSCLC

Nov. 5, 2013

SymBio and Eisai discontinue Japanese phase II trial of Treakisym

Nov. 4, 2013

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Oct. 30, 2013

Vaccine targeting IDO safe and well tolerated in first-in-human study

Oct. 29, 2013

Mologen files application in Belgium to conduct trial in small cell lung cancer

Oct. 29, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...